BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Alembic Pharmaceuticals Ltd. delivered a miss on earnings in Q1 FY22 due to reduced profitability in the U.S. business.
Alembic Pharma exhibited strong performance in the Domestic Formulation segment on the back of a favorable demand scenario, superior execution, and due to a low base in Q1 FY21.
We have lowered our FY22E/FY23E earnings per share estimate by 23%/10% to factor in:
considerable price erosion in the U.S. base business,
delay in successful compliance at Injectable sites due to the ongoing pandemic, and
increased operational cost.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR